Should you buy Royalty Pharma stock now?
Yes, the technical signal for Royalty Pharma is currently BUY. Royalty Pharma trades at $56.91 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.570 with falling momentum (signal: 0.828); RSI is at 51.5 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $61.63 points to 8.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Royalty Pharma stock?
The average analyst price target for Royalty Pharma is $61.63. The current price is $56.91, which gives an upside of 8.3%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $55.47 and $67.79.
Is Royalty Pharma a dividend stock?
Yes, Royalty Pharma is a dividend stock with a dividend yield of 1.57%. The latest dividend was $0.24 per share. The latest ex-dividend date (traded without the dividend) was 8/14/2026. The payout ratio is 23.5%, which is considered sustainable. The next dividend payment is scheduled for 9/10/2026.
When does Royalty Pharma pay a dividend in 2026?
Royalty Pharma pays its next dividend on 9/10/2026. The latest dividend was $0.24 per share with an ex-dividend date of 8/14/2026. The dividend yield is 1.57%. The payout ratio of 23.5% points to a sustainable dividend with room to grow.
What is the risk of Royalty Pharma stock?
Royalty Pharma is rated as a stock with low risk. the annual standard deviation is 22.8%, which classifies the stock as low risk.
Is Royalty Pharma overvalued?
Royalty Pharma is considered fairly valued – the price is close to the analyst price target. Royalty Pharma has the following valuation ratios: a P/E ratio of 30.3 (highly valued), a P/S ratio of 13.6, a P/B ratio of 3.8. The stock trades close to the analyst price target and is considered fairly valued.
Is Royalty Pharma overbought?
No, Royalty Pharma is not overbought. RSI is at 51.5 (neutral zone). The technical indicators show: RSI is at 51.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.8% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Royalty Pharma earnings report?
The date of the next earnings report for Royalty Pharma has not been published yet. Check the company's investor calendar for updates.
Is Royalty Pharma shorted?
Yes, Royalty Pharma is shorted with 2.8% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Royalty Pharma stock?
No, insiders are not buying Royalty Pharma shares – they are net sellers. Over the last 3 months, insiders have made 1 purchases and 8 sales. On a net basis, 13,387,001 $ worth of shares were sold. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 30,554,881 $ sold. Active sellers include Urist Marshall, Hite Christopher, Coyne Terrance P. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Royalty Pharma a good stock?
Based on our total score, Royalty Pharma is rated as a good stock with a total score of 74 out of 100. The stock scores above average on value, quality and momentum – it is among the top 26% in our database. The score is made up of Value: 36/100, Quality: 98/100, Momentum: 88/100. In addition: a dividend of 1.57%; technical signal: Strong Buy. Whether Royalty Pharma is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Royalty Pharma stock?
The outlook for Royalty Pharma based on current data: the average analyst price target is $61.63 (+8.3%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 30.3 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Royalty Pharma stock moving?
Royalty Pharma is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Royalty Pharma go?
The average analyst price target for Royalty Pharma is $61.63, which corresponds to a potential gain of 8.3% from the current price of $56.91. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Royalty Pharma fall?
We lack enough history to give a specific floor for Royalty Pharma. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Royalty Pharma do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Royalty Pharma as an investment.
Did Royalty Pharma raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Royalty Pharma. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Royalty Pharma making money or losing money?
Yes, Royalty Pharma is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 33.9% — which is excellent. The operating margin (profit before interest and taxes) is 100.3%. At a P/E ratio of 30.3, you currently pay 30.3 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Royalty Pharma go bankrupt?
The bankruptcy risk of Royalty Pharma is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.08 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 113% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Royalty Pharma have a lot of debt?
Royalty Pharma has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 113%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
